Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch…


·BYFAVO expected to be commercially available in the US before the end of the year             This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

See the article here:
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch...

Related Posts